The Native Antigen Company recombinant SARS-CoV-2 spike mutants

Click2Contact

Since emerging in 2019, SARS-CoV-2’s genome has proved to be relatively stable. However, the emergence of multiple new variants in late 2020 has caused concern over the efficacy of recently developed countermeasures, including diagnostics, therapeutics and vaccines. Many mutations have occurred in the Spike protein and its receptor-binding domain (RBD), which plays a central role in pathogenesis and the induction of neutralising antibodies.

To support the investigation of SARS-CoV-2 variants, The Native Antigen Company offers a growing range of recombinant mutant spike antigens. Expressed from their proprietary mammalian expression system, these antigens display full glycosylation and proper folding for use in the development of high-performance assays and other applications.

Recombinant mutant antigens are available for the following SARS-CoV-2 lineages (spike mutations): European Variant B1 (D614G); Scotland-1 (D614G, L84I, N439K); England-1 (D614G, S477N); England/Bristol-1 (D614G, V445I, H655Y, E583D); Australia-1 (D614G, G485R); Sweden-1 (D614G, E484K); European Variant B1 (D614G); UK Variant B.1.1.7 (69-70del, Y144del, N501Y, A570D, P681H, T716I, S982A, D1118H); Spanish Variant B1.177 (A222V); and South African Variant 501Y.V2 (D80A, D215G, K417N, E484K, N501Y, A701V).

Currently in development are a range of recombinant antigens of the spike mutations of the following SARS-CoV-2 lineages: UK Variant B.1.1.7 (N501Y); UK Variant B.1.1.7 (+E484K); Brazilian Variant, B1.1.24/P.1; B1.1.298 (Y453F); B1.1 (N501Y, N501Y, D614G); B.1.258, B.1.141/B1.258 (N439K); South African Variant 501Y.V2 (K417N, E484K, N501Y); 69-70 Deletion Mutant (69-70del); and B1.1.28 (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F).